Sangamo Therapeutics announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast

BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 27, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial results after the market closes on Tuesday, May 4, 2021 .